{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06058702",
            "orgStudyIdInfo": {
                "id": "2000036194"
            },
            "secondaryIdInfos": [
                {
                    "id": "RO1",
                    "type": "OTHER",
                    "domain": "National Institute on Drug Abuse"
                }
            ],
            "organization": {
                "fullName": "Yale University",
                "class": "OTHER"
            },
            "briefTitle": "Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans",
            "officialTitle": "Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans",
            "therapeuticArea": [
                "Mental Health",
                "Other"
            ],
            "study": "genetics-of-cannabis-use-disorder-and-cannabinoid-response-in-humans"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-01",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-12-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-09-15",
            "studyFirstSubmitQcDate": "2023-09-21",
            "studyFirstPostDateStruct": {
                "date": "2023-09-28",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-23",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-28",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Deepak C. D'Souza",
                "investigatorTitle": "Albert E. Kent Endowed Professor of Psychiatry",
                "investigatorAffiliation": "Yale University"
            },
            "leadSponsor": {
                "name": "Yale University",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "National Institute on Drug Abuse (NIDA)",
                    "class": "NIH"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "Cannabis is widely used worldwide and is associated with negative outcomes including cannabis use disorder (CanUD), psychosis, and cognitive impairment amongst others. Given the legalization of \"recreational\" and \"medical\" cannabis globally, the increasing availability of cannabis, the higher potency of cannabis, the availability of highly potent cannabinoid products, the commercialization of cannabis, and the rising rates of cannabis use, it is critical to understand how genetic factors influence 1) an individual's vulnerability for addiction and psychosis, 2) the response to cannabinoids, 3) the response to novel treatments for CanUD. CanUD is strongly genetically influenced; the investigators published the first CanUD genomewide association study (GWAS) with genomewide-significant results; however, the precise nature of the contribution of genetic factors in the development of CanUD is still not clear. Cannabis exposure has also been linked to a number of psychosis outcomes including schizophrenia (SCZ). SCZ is highly heritable and population-based and genetics studies both support a bidirectional genetic relationship between SCZ and CanUD. However, the precise contribution of genetic factors in the development of psychosis outcomes related to cannabis are not clear."
        },
        "conditionsModule": {
            "conditions": [
                "Schizophrenia",
                "Cannabis Use Disorder"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "CROSSOVER",
                "primaryPurpose": "OTHER",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 215,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Delta-9-THC",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Active delta-9-THC (0.036 mg/kg) administered intravenously over 20 minutes.",
                    "interventionNames": [
                        "Drug: Delta-9-THC",
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Control: small amount of alcohol administered intravenously (quarter teaspoon), with no delta-9-THC, over 20 minutes.",
                    "interventionNames": [
                        "Drug: Delta-9-THC",
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Delta-9-THC",
                    "description": "Active Delta-9-THC (0.036 mg/kg) administered intravenously over 20 minutes.",
                    "armGroupLabels": [
                        "Delta-9-THC",
                        "Placebo"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Control: Small amount of sterile 190 proof USP ethanol (1-2 mLs), with no THC, administered intravenously over 20 minutes.",
                    "armGroupLabels": [
                        "Delta-9-THC",
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Visual Analog Scale (VAS)",
                    "description": "The VAS is a scale to document perceived reward. A higher score reflects a positive response.",
                    "timeFrame": "Measured at baseline, 20 minutes, 45 minutes, 90 minutes, 140 minutes, 165 minutes, 210 minutes, 270 minutes, and 360 minutes after the start of the initial THC/placebo drug infusion."
                },
                {
                    "measure": "Positive and Negative Symptom Scale (PANSS)",
                    "description": "The Positive and Negative Syndrome Scale is a 30-item scale to assess both the positive and negative symptom symptoms of schizophrenia. The range total score is 30-210. An improvement in symptoms is reflected by a lower score.",
                    "timeFrame": "Measured at baseline, 45 minutes, 90 minutes, 165 minutes, 210 minutes, and 360 minutes after the start of the initial THC/placebo drug infusion."
                },
                {
                    "measure": "Clinician Administered Dissociative Symptoms Scale (CADSS),",
                    "description": "Perceptual alterations will be measured using scales such as the Clinician Administered Dissociative Symptoms Scale (CADSS), a scale consisting of 19 self-report items and 8 clinician-rated items (0 = not at all, 4 = extremely) that we have shown to be sensitive to THC effects. The scale captures alterations in environmental/time/body perception, feelings of unreality, and memory impairment.",
                    "timeFrame": "Measured at baseline, 45 minutes, 90 minutes, 165 minutes, 210 minutes, and 360 minutes after the start of the initial THC/placebo drug infusion."
                },
                {
                    "measure": "CogState Battery",
                    "description": "The CogState Battery measures cognition including verbal learning and recall and episodic memory.",
                    "timeFrame": "Measured at baseline, 45 minutes, and 165 minutes after the start of the initial THC/placebo drug infusion."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n-Ages 18-60 years old\n\nExclusion Criteria:\n\n* Major or unstable medical conditions based on history, the Structured Clinical Interview for DSM-5, collateral information, physical and laboratory examinations, ECG, and vital signs.\n* Cannabis na\u00efve individuals\n* Positive pregnancy test",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "60 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Deepak D'Souza, MD",
                    "role": "CONTACT",
                    "phone": "203-932-5711",
                    "phoneExt": "12594",
                    "email": "deepak.douza@yale.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Deepak D'Souza, MD",
                    "affiliation": "Yale University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "West Haven Veterans Affairs Medical Center",
                    "city": "West Haven",
                    "state": "Connecticut",
                    "zip": "06516",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Deepak C D'Souza, MD",
                            "role": "CONTACT",
                            "phone": "203-932-5711",
                            "phoneExt": "12594",
                            "email": "deepak.dsouza@yale.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.27065,
                        "lon": -72.94705
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002189",
                    "term": "Marijuana Abuse"
                },
                {
                    "id": "D000012559",
                    "term": "Schizophrenia"
                }
            ],
            "ancestors": [
                {
                    "id": "D000019967",
                    "term": "Schizophrenia Spectrum and Other Psychotic Disorders"
                },
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                },
                {
                    "id": "D000019966",
                    "term": "Substance-Related Disorders"
                },
                {
                    "id": "D000064419",
                    "term": "Chemically-Induced Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M15376",
                    "name": "Schizophrenia",
                    "asFound": "Schizophrenia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5449",
                    "name": "Marijuana Abuse",
                    "asFound": "Cannabis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21838",
                    "name": "Schizophrenia Spectrum and Other Psychotic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M21837",
                    "name": "Substance-Related Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M30302",
                    "name": "Chemically-Induced Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC25",
                    "name": "Substance Related Disorders"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000013759",
                    "term": "Dronabinol"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006213",
                    "term": "Hallucinogens"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000011619",
                    "term": "Psychotropic Drugs"
                },
                {
                    "id": "D000018712",
                    "term": "Analgesics, Non-Narcotic"
                },
                {
                    "id": "D000000700",
                    "term": "Analgesics"
                },
                {
                    "id": "D000018689",
                    "term": "Sensory System Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000063386",
                    "term": "Cannabinoid Receptor Agonists"
                },
                {
                    "id": "D000063385",
                    "term": "Cannabinoid Receptor Modulators"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3777",
                    "name": "Ethanol",
                    "relevance": "LOW"
                },
                {
                    "id": "M16527",
                    "name": "Dronabinol",
                    "asFound": "Refractory anemia with excess blasts",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9305",
                    "name": "Hallucinogens",
                    "relevance": "LOW"
                },
                {
                    "id": "M14474",
                    "name": "Psychotropic Drugs",
                    "relevance": "LOW"
                },
                {
                    "id": "M4032",
                    "name": "Analgesics",
                    "relevance": "LOW"
                },
                {
                    "id": "M20786",
                    "name": "Analgesics, Non-Narcotic",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infe",
                    "name": "Anti-Infective Agents"
                },
                {
                    "abbrev": "CNSDep",
                    "name": "Central Nervous System Depressants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                },
                {
                    "abbrev": "PsychDr",
                    "name": "Psychotropic Drugs"
                }
            ]
        }
    },
    "hasResults": false
}